Abstract: Provided is a method for treating an oil gas, which can realize high-efficiency separation for and recovery of gasoline components, C2, C3, and C4 components. The method first conducts separation of light hydrocarbon components from gasoline components, and then performs subsequent treatment on a stream rich in the light hydrocarbon components, during which it is no longer necessary to use gasoline to circularly absorb liquefied gas components, which significantly reduces the amount of gasoline to be circulated and reduces energy consumption throughout the separation process. Besides, in this method, impurities, such as H2S and mercaptans, in the stream rich in the light hydrocarbon components are removed first before the separation for the components. This ensures that impurities will not be carried to a downstream light hydrocarbon recovery section, thus avoiding corrosion issues caused by hydrogen sulfide in the light hydrocarbon recovery section.

Abstract: The present invention relates to a microplastic detection device and method based on a pyrolysis-mass spectrometry technology. The microplastic detection device based on a pyrolysis-mass spectrometry technology provided by the present invention is substantially a sealed gas path device system formed connected via pipelines. The device includes a working gas source, a pyrolysis device, a filter and a mass spectrometer which are connected in sequence. After a microplastic sample is placed into the pyrolysis device, the microplastic sample is decomposed in the pyrolysis device, and pyrolysis products from the microplastic sample driven by a carrier gas of the working gas source enter the mass spectrometer for detection and analysis after being filtered by the filter. Furthermore, the present invention provides a microplastic detection method based on a pyrolysis-mass spectrometry. The present invention is widely applied to the field of a microplastic detection technology.

Abstract: A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and/or treating thrombotic diseases.

Abstract: A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and/or treating thrombotic diseases.

Abstract: Provided is the use of a CSF1R kinase inhibitor compound or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating diseases related to the CSF1R kinase signal transduction pathway or drugs for regulating immunization.

Abstract: A use of a compound as a CYP2E1 inhibitor includes: using a compound shown in formula (I) or a salt thereof as an inhibitor to inhibit CYP2E1, where the compound or the salt thereof targets and binds to CYP2E1. The inhibitor can be used for the prevention and treatment of a tumor including liver cancer, glioma, ovarian cancer, lung cancer, bladder cancer, and gallbladder cancer. The inhibitor can also be used for the prevention and treatment of an inflammation-mediated disease (IMD) such as liver damage, fatty liver, hepatitis, liver fibrosis, pulmonary fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease (AD), ischemic stroke, Parkinson's disease (PD), hyperlipidemia, atherosclerosis (AS), coronary heart disease (CHD), and diabetes.

Abstract: A novel indazole compound, a preparation method therefor, and use thereof in the preparation of drugs for treating related diseases. Specifically disclosed are a compound of formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a compound as shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer, an isotope derivative or a prodrug thereof. The compound has an excellent activity as a cyclin-dependent kinase 9 (CDK9) inhibitor for treating hyperproliferative diseases. The experimental research on in vitro inhibition of cell proliferation and in vivo suppression of tumors shows that such compounds have a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and have a good selectivity and a low toxicity and few side effects, thereby possessing a good clinical value as novel anti-tumor drugs.

Abstract: Provided is a method for treating an oil gas, which can realize high-efficiency separation for and recovery of gasoline components, C2, C3, and C4 components. The method first conducts separation of light hydrocarbon components from gasoline components, and then performs subsequent treatment on a stream rich in the light hydrocarbon components, during which it is no longer necessary to use gasoline to circularly absorb liquefied gas components, which significantly reduces the amount of gasoline to be circulated and reduces energy consumption throughout the separation process. Besides, in this method, impurities, such as H2S and mercaptans, in the stream rich in the light hydrocarbon components are removed first before the separation for the components. This ensures that impurities will not be carried to a downstream light hydrocarbon recovery section, thus avoiding corrosion issues caused by hydrogen sulfide in the light hydrocarbon recovery section.

Abstract: A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and/or treating thrombotic diseases.

Abstract: The present invention discloses a molecular beam epitaxy under vector strong magnetic field and an in-situ characterization apparatus thereof. The apparatus mainly consists of an inverted T-shaped ultrahigh vacuum growth and characterization chamber with a compact structure and a strong magnet. The inverted T-shaped vacuum chamber portion, which disposed in the room-temperature chamber of the strong magnet, includes a compact epitaxial growth sample stage, a device capable of rotating angle between the growth and magnetic field directions, and an in-situ characterization apparatus. The portion disposed below the strong magnet includes a molecular beam source component such as evaporation source, plasma source etc., and a vacuum-pumping system.

Abstract: Disclosed are a Fuc3S4S substituted oligoglycosaminoglycan with a weight-average molecular weight (Mw) of about 4.5-9 kD, a pharmaceutical composition containing the Fuc3S4S substituted oligoglycosaminoglycan, a preparation method thereof and a use thereof in preparing medicines for preventing and/or treating thrombotic diseases.

Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.

Abstract: A low-molecular-weight fucosylated glycosaminoglycan (aTFG) containing 2,5-anhydrated talose, alditol, glycosylamine or N-substituted glycosylamine monosaccharide composition thereof, preparation method thereof, pharmaceutical compositions containing the aTFG, and use thereof for preventing and/or treating thrombotic diseases are provided. The aTFG has potent anticoagulant activity targeting at intrinsic coagulation factor Xase, and inhibiting thrombogenesis, and therefore can be used as drugs for preventing and/or treating cardiovascular and cerebrovascular diseases.

Abstract: This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.

Abstract: The supporting of debugging of failed vertex code on a test machine. This debugging is made possible even though the vertex code failed while on a remote processing node, and is but one of multiple, and potentially innumerable vertices that run in a distributed environment. This represents a vast technical improvement over prior ad hoc methods for trying to debug a large distributed application, since time is not wasted on vertices that operated properly, but rather debugging is focused on the problem vertex. Even reproducing the failure is a huge technical step forward.

Abstract: The present invention discloses a molecular beam epitaxy under vector strong magnetic field and an in-situ characterization apparatus thereof. The apparatus mainly consists of an inverted T-shaped ultrahigh vacuum growth and characterization chamber with a compact structure and a strong magnet. The inverted T-shaped vacuum chamber portion, which disposed in the room-temperature chamber of the strong magnet, includes a compact epitaxial growth sample stage, a device capable of rotating angle between the growth and magnetic field directions, and an in-situ characterization apparatus. The portion disposed below the strong magnet includes a molecular beam source component such as evaporation source, plasma source etc., and a vacuum-pumping system.

Abstract: Provided are a low-molecular-weight fucosylated glycosaminoglycan derivative (derivative of Low molecular weight Fucosylated Glycosaminoglycan, dLFG) having anticoagulant activity, a preparation method thereof, a pharmaceutical composition comprising dLFG or a pharmaceutically acceptable salt thereof, and the use of dLFG and pharmaceutical composition thereof in preparing medicine for treating thrombotic diseases.

Abstract: This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.

Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.